Home/Filings/4/0001209191-09-049097
4//SEC Filing

WYETH 4

Accession 0001209191-09-049097

CIK 0000005187operating

Filed

Oct 18, 8:00 PM ET

Accepted

Oct 19, 5:19 PM ET

Size

21.3 KB

Accession

0001209191-09-049097

Insider Transaction Report

Form 4
Period: 2009-10-15
Krebs Andreas
President, EMEA & Canada
Transactions
  • Disposition to Issuer

    Common Stock

    2009-10-15$49.58/sh4,040$200,30311,842.738 total
  • Disposition to Issuer

    Common Stock

    2009-10-1511,842.7380 total
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$10.30/sh4,000$41,2000 total
    Exercise: $39.28Common Stock (4,000 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$6.01/sh11,000$66,1100 total
    Exercise: $43.57Common Stock (11,000 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-1515,7600 total
    Exercise: $56.00Common Stock (15,760 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$9.36/sh4,668$43,6920 total
    Exercise: $40.22Common Stock (4,668 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$1.36/sh17,500$23,8000 total
    Exercise: $48.22Common Stock (17,500 underlying)
  • Disposition to Issuer

    Employee Stock Option

    2009-10-15$5.02/sh16,560$83,1310 total
    Exercise: $44.56Common Stock (16,560 underlying)
Footnotes (5)
  • [F1]Represents restricted stock units.
  • [F2]Pursuant to the Agreement and Plan of Merger by and among Wyeth, Pfizer Inc. and Wagner Acquisition Corp., dated as of January 25, 2009 (as amended, the "Merger Agreement"), each restricted stock unit was cancelled at the effective time of the merger in exchange for cash equal to the per share value of the merger consideration of $49.58, less any applicable tax withholding.
  • [F3]Represents Wyeth common stock.
  • [F4]Pursuant to the Merger Agreement, each of these shares was cancelled at the effective time of the merger and converted into the right to receive $33.00 in cash and 0.985 of a share of Pfizer Inc. common stock, less any applicable tax withholding.
  • [F5]Pursuant to the Merger Agreement, each outstanding and unexercised option, whether vested or unvested, was cancelled at the effective time of the merger in exchange for cash equal to the product of (a) the number of shares underlying such option and (b) the excess, if any, of the per share value of the merger consideration of $49.58 over the per share exercise price of the option, less any applicable tax withholding.

Issuer

WYETH

CIK 0000005187

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000005187

Filing Metadata

Form type
4
Filed
Oct 18, 8:00 PM ET
Accepted
Oct 19, 5:19 PM ET
Size
21.3 KB